Reason for comment York Pharma have announced the acquisition of the sales and worldwide commercial rights to two dermatological products from the Belgian Pharmaceutical and Chemical Company Solvay for a total consideration of €28.5m.

The products are Flammazine® and Flammacerium®, both brands are established in Europe for the prevention of infection in burns and topical wounds. The agreement with Solvay entails the transfer of the brands, any IP and sales on a worldwide basis as well as an associated 5 year supply contract of finished product from Solvay.

These silver-based sulfadiazine (anti-bacterial) products are approved in 21 countries although sales of the product are concentrated in France, Germany, Belgium and Spain. York estimates that the global market for topical anti-infectives is valued around US$450million with the current sales of these products around the $17.2 million (£ 8.7 million) mark or a penetration of 3.8%.

To finance this acquisition, York has

...